INMB director Marcia Allen reports one-time stock option repricing
Rhea-AI Filing Summary
Inmune Bio, Inc. (INMB) director Marcia Allen reported a repricing of her stock options, following stockholder approval effective November 18, 2025. Certain existing options granted under the company’s 2017, 2019 and 2021 stock incentive plans had their exercise price reduced to $1.50 per share, matching the Nasdaq closing price of Inmune Bio’s common stock on the repricing date. The filing shows prior options with higher exercise prices, including awards at $3.91, $7.92, $9.74, $17.49, $24.82 and $5.05, being adjusted so that the same numbers of underlying shares remain, but at the new exercise price. All other terms of these options, such as vesting schedules and expiration dates, remain unchanged, and the awards continue to be tied to Allen’s ongoing service with the company.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Stock Option (right to buy) | 108,000 | $0.00 | -- |
| Grant/Award | Stock Option (right to buy) | 108,000 | $0.00 | -- |
| Disposition | Stock Option (right to buy) | 15,975 | $0.00 | -- |
| Grant/Award | Stock Option (right to buy) | 15,975 | $0.00 | -- |
| Disposition | Stock Option (right to buy) | 19,025 | $0.00 | -- |
| Grant/Award | Stock Option (right to buy) | 19,025 | $0.00 | -- |
| Disposition | Stock Option (right to buy) | 35,000 | $0.00 | -- |
| Grant/Award | Stock Option (right to buy) | 35,000 | $0.00 | -- |
| Disposition | Stock Option (right to buy) | 35,000 | $0.00 | -- |
| Grant/Award | Stock Option (right to buy) | 35,000 | $0.00 | -- |
| Disposition | Stock Option (right to buy) | 32,500 | $0.00 | -- |
| Grant/Award | Stock Option (right to buy) | 32,500 | $0.00 | -- |
| Disposition | Stock Option (right to buy) | 12,500 | $0.00 | -- |
| Grant/Award | Stock Option (right to buy) | 12,500 | $0.00 | -- |
Footnotes (1)
- Effective as of November 18, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2017 Stock Incentive Plan (the "2017 Plan"), 2019 Stock Incentive Plan (the "2019 Plan"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the "2021 Plan") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.
FAQ
What did Inmune Bio (INMB) disclose in this Form 4 filing?
The filing reports that director Marcia Allen had several existing stock option grants repriced, with their exercise price reduced to $1.50 per share, effective November 18, 2025, while retaining the same number of underlying shares and other existing terms.
Why were Marcia Allen’s Inmune Bio stock options repriced to $1.50?
The options were adjusted as part of a one-time repricing approved by Inmune Bio’s stockholders, which reset the exercise price of certain outstanding options to $1.50, the closing price of the company’s common stock on The Nasdaq Capital Market on the repricing date.
Which Inmune Bio stock incentive plans are involved in this option repricing?
The repriced options were originally granted under Inmune Bio’s 2017 Stock Incentive Plan, 2019 Stock Incentive Plan and the Second Amended and Restated 2021 Stock Incentive Plan, and continue to be governed by those plans.
How did the repricing affect the terms of Marcia Allen’s Inmune Bio options?
Only the exercise price of the affected options was changed to $1.50 per share. The filing states that all other terms and conditions, including vesting provisions and the term of the options, remain in full force and effect.
What were some of the previous exercise prices of the repriced Inmune Bio options?
The report lists prior option grants with higher exercise prices, including awards at $3.91, $7.92, $9.74, $17.49, $24.82 and $5.05, which were adjusted so that the same number of shares are now exercisable at $1.50.
Does Marcia Allen’s continued service affect these Inmune Bio option awards?
Yes. The filing notes that the options become exercisable in line with the existing vesting schedule specified in the award agreements and remain subject to her continued service with Inmune Bio as of each vesting date.